Changes of cytokine levels during granulocyte–colony-stimulating factor stem cell mobilization in healthy donors: association with mobilization efficiency and potential predictive significance
Daniel Lysák
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorMarcela Hrabětová
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorJindra Vrzalová
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorVladimír Koza
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorJana Navrátilová
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorTomáš Svoboda
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorAlexandra Jungová
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorOndřej Topolčan
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorDaniel Lysák
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorMarcela Hrabětová
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorJindra Vrzalová
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorVladimír Koza
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorJana Navrátilová
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorTomáš Svoboda
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorAlexandra Jungová
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorOndřej Topolčan
From the Department of Hematology and Oncology, University Hospital Pilsen, Czech Republic, Czech National Marrow Donor Registry (CS2); and the Laboratory of Immunoanalysis, Department of Nuclear Medicine, University Hospital Pilsen, Pilsen, Czech Republic.
Search for more papers by this authorAbstract
BACKGROUND: Peripheral blood stem cells are an important source of hematopoietic stem cells (HSCs) for allogeneic transplantations. Some allogeneic donors mobilize HSCs poorly in response to the granulocyte—colony-stimulating factor (G-CSF). The estimation of the mobilization result in an individual donor is difficult due to the absence of suitable predictive factors.
STUDY DESIGN AND METHODS: We analyzed the concentrations and kinetics of certain cytokines induced by G-CSF in 76 healthy donors and compared them with the mobilization efficiency.
RESULTS: The levels of the most cytokines increased after the G-CSF application: sICAM, sVCAM, MMP-9, interleukin (IL)-6, TNF-α, sE-selectin, and fibronectin. The concentrations of SDF-1α and IL-8 decreased and VEGF and fractalkine remained unchanged. The premobilization concentrations of IL-6 (p = 0.0093) and TNF-a (p = 0.0006) correlated with preapheresis CD34+ cell count. The comparison of premobilization cytokine levels between better and worse mobilizers showed a difference for TNF-α (p = 0.0006) and IL-6 (p = 0.0682). The TNF-α level below cutoff of 3.6 pg/mL implied approximately 20 times higher risk of poor mobilization (odds ratio, 19.9; p = 0.0002). The immunophenotyping of CD34+ cells suggested a negative correlation between Day +5 CD34+ count and expression of CD11a (p = 0.0319) and a positive correlation with CD44 antigen expression (p = 0.0096).
CONCLUSION: The concentrations of certain cytokines corresponded to the quality of HSC mobilization in healthy donors. Their levels measured before mobilization could probably serve as predictive factors for mobilization efficacy and prospectively detect donors who might profit from new mobilization molecules.
REFERENCES
- 1 Carstanjen D, Regenfus M, Müller C, Salama A. Interleukin-6 is a major effector molecule of short-term G-CSF treatment inducing bone metabolism and an acute- phase response. Exp Hematol 2001; 29: 812-821.
- 2 Weidt C, Niggemann B, Kasenda B, Drell TL, Zänker KS, Dittmar T. Stem cell migration: a quintessential stepping stone to successful therapy. Curr Stem Cell Res Ther 2007; 2: 89-103.
- 3 Watanabe T, Kawano Y, Kanamaru S, Onishi T, Kaneko Y, Wakata Y, Nakagawa R, Makimoto A, Kuroda Y, Takaue Y, Talmadge JE. Endogenous interleukin-8 (IL-8) surge in granulocyte colony- stimulating factor- induced peripheral blood stem cell mobilization. Blood 1999; 93: 1157-1163.
- 4 Vermulen M, LePasteur F, Gagnerault MC, Mary JY, Sainteny F, Lepault F. Role of adhesion molecules in the homing and mobilization of murine hematopoietic stem and progenitor cells Blood 1998; 92: 894-900.
- 5 Kikuta T, Shimazaki C, Ashihara E, Sudo Y, Hirai H, Sumikuma T, Yamagata N, Inaba T, Fujita N, Kina T, Nakagawa M. Mobilization of hematopoietic primitive and committed progenitor cells into blood in mice by anti-vascular adhesion molecule-1 antibody alone or in combination with granulocyte colony stimulating factor. Exp Hematol 2000; 8: 311-317.
- 6 Avigdor A, Goichberg P, Shivtiel S, Ayelet D, Amnon P, Sarit S, Orit K, Rami H, Ronen A, Izhar H, Herzl BH, Naor D, Nagler A, Lapidot T. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 2004; 103: 2981-2989.
- 7 Zeller W, Kröger N, Berger J, Krueger W, Dierlamm J, Stockschläder M, Gutensohn K, Hossfeld DK, Zander AR. Expression of the adhesion molecules CD49d and CD49e on G-CSF- mobilized CD34+ cells of patients with solid tumors or non- Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CVD34+ cells. J Hematother Stem Cell Res 1999; 8: 539-546.
- 8 Prosper F, Stroncek D, McCarthy JB, Verfaillie CM. Mobilization and homing of peripheral blood progenitors is related to reversible downregulation of α4 β1 integrin expression and function. J Clin Invest 1998; 101: 2456.
- 9 Lee S, Im SA, Yoo ES, Nam EM, Lee MA, Ahn JY, Huh JW, Kim DY, Lee SN, Kim MJ, Lee SJ, Chung WS, Seong CM. Mobilization kinetics of CD34+ cells with modulation of CD44 and CD31 expression during continuous intravenous administration of G-CSF in normal donors. Stem Cells 2000; 18: 281-286.
- 10 Winkler IG, Levesque JP. Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone. Exp Hematol 2009; 34: 996-1009.
- 11 Semerad CL, Christopher MJ, Liu F, Short B, Simmons PJ, Winkler I, Levesque JP, Chappel J, Ross FP, Link DC. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005; 106: 3020-3027.
- 12 Winkler IG, Hendy J, Coughlin P, Horvath A, Lévesque JP. Serine protease inhibitors serpina1 and serpina3 are down-regulated in bone marrow during hematopoietic progenitor mobilization. J Exp Med 2005; 201: 1077-1088.
- 13 Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ. Peripheral blood stem cell yield in 400 normal donors mobilized with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 2006; 134: 517-525.
- 14 Martino M, Callea I, Condemi A, Dattola A, Irrera G, Marcuccio D, Messina G, Pontari A, Pucci G, Console G, Lacopino P. Predictive factors that affect the mobilization of CD34+cells in healthy donors treated with recombinant granulocyte colony- stimulating factor (G-CSF). J Clin Apheresis 2006; 21: 169-175.
- 15 Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ, Champlin RE, Körbling M. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 1999; 39: 555-560.
- 16 De la Rubia J, Arbona C, de Arriba F, del Cañizo C, Brunet S, Zamora C, Díaz MA, Bargay J, Petit J, de la Serna J, Insunza A, Arrieta R, Pascual MJ, Serrano D, Sanjuan I, Espigado I, Alegre A, Martínez D, Verdeguer A, Martínez C, Benlloch L, Sanz MA. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion 2002; 42: 4-9.
- 17 Levesque JP, Winkler I. Mobilization of hematopoietic stem cells: state of the art. Curr Opin Organ Transplant 2008; 13: 53-58.
- 18 Gazitt Y, Shaughnessy P, Liu Q. Expression of adhesion molecules on CD34+ cells in peripheral blood of non- Hodgkin's lymphoma patients mobilized with different growth factors. Stem Cells 2001; 19: 134-143.
- 19 Möhle R, Murea S, Kirsch M, Haas R. Differential expression of L-selectin, VLA-4, and LFA-1 on CD34+ progenitor cells from bone marrow and peripheral blood during G-CSF- enhanced recovery. Exp Hematol 1995; 23: 1535-1542.
- 20 Bellucci R, De Propris MS, Buccisano F, Lisci A, Leone G, Tabilio A, de Fabritiis P. Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. Bone Marrow Transplant 1999; 23: 1-8.
- 21 Dosquet C, Chen Y, Makke J, Miclea JM, Coudert MC, Marolleau JP, Fermand JP, Cottu P, Lotz JP, Benbunan M. Cytokines and vascular adhesion molecule-1 in the blood of patients undergoing HPC mobilization. Transfusion 2001; 41: 206-212.
- 22 Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
- 23 Suzuya H, Watanabe T, Nakagawa R, Watanabe H, Okamoto Y, Onishi T, Abe T, Kawano Y, Kagami S, Takaue Y. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang 2005; 89: 229-235.
- 24 Südhoff T, Söhngen D. Circulating endothelial adhesion molecules (sE-selectin, sVCAM-1 and sICAM-1) during rHuG-CSF-stimulated stem cell mobilization. J Hematother 2002; 11: 147-151.
- 25 Carstanjen D, Ulbricht N, Iacone A, Regenfus M, Salama A. Matrix metalloproteinase-9 (gelatinase B) is elevated during mobilization of peripheral blood progenitor cells by G-CSF. Transfusion 2002; 42: 588-596.
- 26 Li CX, Wu DP, Chang WR, Zhu HT, Cen JN, Zhang XG. Dynamics changes of cytokines in G-CSF mobilized peripheral blood. Zhonghua Xue Ye Xue Za Zhi 2003; 24: 398-401.
- 27 Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by G-CSF or cyclophosphamide. J Clin Invest 2003; 111: 187-196.
- 28 Lysák D, Jungová A, Vrzalová J, Holubec L, Koza V. Correlation of cytokines levels and adhesion molecules expression with stem cell mobilization efficacy in healthy donors. Blood (ASH Annual Meeting Abstracts) 2008; 112: 3466.
- 29 Ford CD, Greenwood J, Anderson J, Snow G, Petersen FB. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor. Transfusion 2006; 46: 193-198.
- 30 Oelschlaegel U, Bornhauser M, Boxberger S, Kroschinsky F, Illmer T, Hoelig K, Calandra G, Ehninger G, Platzbecker U. Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilization with G-CSF plus AMD3100 in patients with multiple myeloma. Ann Hematol 2007; 86: 569-573.
- 31 Sovalat H, Racadot E, Ojeda M, Lewandowski H, Chabouté V, Hénon P. CD34+ cells and CD34+CD38- subset from mobilized blood show different patterns of adhesion molecules compared to those from steady-state blood, bone marrow, and cord blood. J Hematother Stem Cell Res 2003; 12: 473-489.
- 32 Oelschlaegel U, Ehninger G, Kroschinsky F. Differences in expression of adhesion molecules in correlation to mobilization efficacy in healthy stem cell donors investigated by flow cytometry. Bone Marrow Transplant 2004; 33: S131.